Vedolizumab
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
Product Specifications
CAS Number
943609-66-3
Product Name Alternative
Anti-Human lymphocyte α4β7 integrin, Humanized Antibody; LDP-02; MLN-002
UNSPSC
12352203
Target
Integrin
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/Vedolizumab.html
Purity
99.90
Solubility
10 mM in H2O
Smiles
[Vedolizumab]
Molecular Weight
(146.868 kDa)
References & Citations
[1]Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330 (3) :864-75.|[2]Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7 (1) :4-9.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
ICH1133-100mg 100 mg
Anti-Mouse Tim-3 (RMT3-23) In Vivo Antibody - Low Endotoxin
Sign In for Pricing
View Details 
